# CABOSUN (NCT01835158)

> Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

No report yet. It can be ordered.

- Drugs tested: cabozantinib
- Indication: untreated advanced clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01835158
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
- Interventions: Cabozantinib S-malate; Laboratory Biomarker Analysis; Sunitinib Malate
- Enrollment: 157
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on CABOSUN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 27
- Podcasts: 5
- YouTube: 4

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cabosun-nct01835158

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01835158", "email": "<work email>"}; the inbox owner confirms by the emailed link.